PT  - JOURNAL ARTICLE
AU  - Saskia Litière
AU  - Jan Bogaerts
TI  - Imaging endpoints for clinical trial use: a RECIST perspective
AID  - 10.1136/jitc-2022-005092
DP  - 2022 Nov 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e005092
VI  - 10
IP  - 11
4099  - http://jitc.bmj.com/content/10/11/e005092.short
4100  - http://jitc.bmj.com/content/10/11/e005092.full
SO  - J Immunother Cancer2022 Nov 01; 10
AB  - Twenty years after its initial introduction, Response Evaluation Criteria in Solid Tumors (RECIST) remains today a unique standardized tool allowing uniform objective evaluation of response in solid tumors in clinical trials across different treatment indications. Several attempts have been made to update or replace RECIST, but none have realized the general traction or uptake seen with RECIST. This communication provides an overview of some challenges faced by RECIST in the rapidly changing oncology landscape, including the incorporation of PET with 18F-fluorodeoxyglucose tracer as a tool for response assessment and the validation of criteria for use in trials involving immunotherapeutics. The latter has mainly been slow due to lack of data sharing. Work is ongoing to try to address this.We also aim to share our view as statistician representatives on the RECIST Working Group on what would be needed to validate new imaging endpoints for clinical trial use, with a specific focus on RECIST. Whether this could lead to an update of RECIST or replace RECIST altogether, depends on the changes being proposed. The ultimate goal remains to have a well defined, repeatable, confirmable and objective standard as provided by RECIST today.